First-in-class combination therapy of a copper(II) metallo-phosphorus dendrimer with cytotoxic agents - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Oncology Année : 2018

First-in-class combination therapy of a copper(II) metallo-phosphorus dendrimer with cytotoxic agents

Résumé

The metallo-phosphorus dendrimer 1G3-Cu (generation 3 dendrimer bearing 48 conjugated copper(II) on its surface) has antiproliferative activity related to its capacity to activate Bax translocation. In the present study, we evaluate the activity of an association of 1G3-Cu with 5 cytotoxic agents used in chemotherapy having different modes of action. Data show no additive effect with camptothecin and cisplatin, additivity with paclitaxel and MG132, and synergy with doxorubicin. Results suggest that the multivalent Cu-conjugated dendrimer 1G3-Cu (activator of Bax translocation) plays an important role in boosting the clinical impact of Bax accumulation stimulated by the proteasome inhibitor MG132, antimitotic taxanes, and the topo II inhibitor doxorubicin.
Fichier non déposé

Dates et versions

hal-01957977 , version 1 (17-12-2018)

Identifiants

Citer

Serge Mignani, Nabil El brahmi, T. Cresteil, Jean Pierre Majoral. First-in-class combination therapy of a copper(II) metallo-phosphorus dendrimer with cytotoxic agents. Oncology, 2018, 94 (5), pp.324-328. ⟨10.1159/000486680⟩. ⟨hal-01957977⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More